There’s no question that pancreatic cancer is a challenging disease to treat. National statistics reveal several hard truths: Survival rates remain unacceptably poor.
“I wish I had known sooner that the persistent stomach pain I experienced prior to my diagnosis was a symptom of pancreatic cancer,” Alex Trebek told viewers.
Pancreatic cancer is called a silent killer because it often grows or spreads undetected. And like many cancers, it presents few warning signs. It’s critically important to educate patients about the options and the importance of early detection.
On January 29, the Food and Drug Administration approved a lutetium Lu 177 dotatate (Lutathera®), a targeted radiation drug, for the treatment of gastroenteropancreatic neuroendocrine tumors.
Pathologists are key partners of the medical team whose investigations and findings are essential to successful surgical and treatment plans for cancer patients.
When diagnosing or treating cancer, a less-invasive procedure often leads to better outcomes and fewer risks.
Pancreatic cancer is one of the deadliest diseases in the world and the fourth leading cause of cancer death in the United States. A major contributing factor for pancreatic cancer’s high death rate is a lack of effective early detection or screening tests.